Alzheimer’s disease currently affects nearly 6 million Americans. It is estimated that by the year 2050, this disease could affect 160 million people worldwide. Until now, this disease was uniformly fatal. There was no cure. The few approved drugs only slowed the decline for a brief time.
“Everyone knows someone who is a cancer survivor; no one knows an Alzheimer’s survivor….until now.” Dr Dale Bredesen.
Since 2014, this statement is no longer true. In that year, Dr. Bredesen, of the UCLA Buck Institute for Aging Research, published his landmark paper describing the reversal of the dementia symptoms in patients with Alzheimer’s Disease.1 That initial study on 10 patients has now expanded to hundreds.
The first patient is nearly 6 years into treatment and continues with normal cognition. The results have been replicated in hundreds of patients since.
His treatment protocol is named ReCODE (Reversal of Cognitive Decline). Dr. Bredesen followed up his scientific publications with a New York Times best-selling book, The End of Alzheimer’s.
Dr. Bredesen began to train other physicians in the ReCODE protocol. Dr. Koziarski was one of the physicians included in the early training program.